Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tree MATA MPL Immunogenicity in Tree Pollen Allergy
NCT00113750Phase 2Completed
- Sponsor
- Allergy Therapeutics PLC
- Start
- Jul 2005
- Modality
- Prophylactic Vaccines, Subcutaneous Immunotherapy, Sublingual Immunotherapy
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in seasonal allergic rhinoconjunctivitis (SARC) comparing Tree MATA MPL with Placebo (2 arms). Primary endpoint: Post-injection antibody response to birch. Started Jul 2005; status: completed.
02
Drugs
Tree MATA MPL
03
Conditions
seasonal allergic rhinoconjunctivitis (SARC)
Beyond the preview
Go deeper on NCT00113750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00113750.